Record full year 2022 net sales of $ 8.6 million increased 58 % over $ 5.5 million for full year 2021 Company to host conference call and webcast today, March 8, 2023 at 4:30pm EST ROCKAWAY, N.J. , March 08, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (the “Company”), a
Record full year 2023 net sales of $ 16.0 million increased 87% over $8 .6 million for the full year 2022 Company to host conference call and webcast today, March 13, 2024 at 4:30pm EST ROCKAWAY, N.J. , March 13, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc.
BASKING RIDGE, N.J. , June 10, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Frank R. Amato will be stepping down as Chief Executive Officer. Mr. Amato joined electroCore in 2012 and was named Chief Executive
ROCKAWAY, N.J. , Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-VENUS study of non-invasive vagal nerve stimulation (nVNS) for the acute treatment of stroke.
LONDON , and BASKING RIDGE, N.J. , June 24, 2019 (GLOBE NEWSWIRE) -- electroCore, Inc. (“electroCore”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that gammaCore TM , the company’s non-invasive vagus nerve stimulator (nVNS), will appear on the NHS Supply
ROCKAWAY, NJ , July 27, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,065,444 to electroCore, relating to the use of a mobile
ROCKAWAY, N.J. , Dec. 07, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued two patents related to its non-invasive vagus nerve stimulation (nVNS)
ROCKAWAY, N.J. , June 23, 2022 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”) (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has received approval from the Nasdaq Stock Market (“Nasdaq”) to transfer the listing of its common stock from the Nasdaq
ROCKAWAY, NJ , Sept. 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office has issued US Patent No. 11,097,102 to electroCore, relating to devices, systems and methods
ROCKAWAY, NJ , Dec. 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, today announced that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No.